Glycosaminoglycans, protein aggregation and neurodegeneration

Current Protein and Peptide Science

Volumn 12, Issue 3, 2011, Pages 258-268

  Papy Garcia, Dulce ^a   Christophe, Morin ^a   Bao, Huynh Minh ^a   Fernando, Siñeriz ^c   Ludmilla, Sissoeff ^a   Elisa, Sepúlveda Díaz Julia ^a   Rita, Raisman Vozari ^b  

^a Faculté des Sciences et Technologie ^*  (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c OTR3 SAS   (France)

Author keywords

A 42; Glycosaminoglycans; Heparan sulfate; Neurodegeneration; Prion; Protein aggregation; Tau; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; BETA 2 MICROGLOBULIN; CHONDROITIN SULFATE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DISACCHARIDE; EPIMERASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; GLYCOSAMINOGLYCAN; GLYPICAN; HEPARAN SULFATE; HYALURONIC ACID; IDURONIC ACID; KERATAN SULFATE; N ACETYLGALACTOSAMINE; N ACETYLGLUCOSAMINE; PERLECAN; PRION PROTEIN; PROTEOGLYCAN; SERUM AMYLOID A; SYNDECAN; TAU PROTEIN; URONIC ACID;

ALZHEIMER DISEASE; CALCIUM HOMEOSTASIS; CREUTZFELDT JAKOB DISEASE; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM; EPIMERIZATION; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; MOLECULAR DYNAMICS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE FIBER; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

EID: 79959311966     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/138920311795860188     Document Type: Review

References (108)

1. Lin, C.Y.; Gurlo, T.; Kayed, R.; Butler, A.E.; Haataja, L.; Glabe, C.G.; Butler, P.C., Toxic human islet amyloid polypeptide (h- IAPP) oligomers are intracellular, and vaccination to induce antitoxic oligomer antibodies does not prevent h-IAPP-induced betacell apoptosis in h-IAPP transgenic mice. Diabetes, 2007, 56 (5), 1324-32.
2. Bretteville, A.; Planel, E., Tau aggregates: toxic, inert, or protective species? J. Alzheimers Dis., 2008, 14 (4), 431-6.
3. Cohlberg, J.A.; Li, J.; Uversky, V.N.; Fink, A.L., Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry, 2002, 41 (5), 1502-11.
4. Diaz-Nido, J.; Wandosell, F.; Avila, J., Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides, 2002, 23 (7), 1323-32.
5. Gandhi, N.S.; Mancera, R.L., The structure of glycosaminoglycans and their interactions with proteins. Chem. Biol. Drug Des., 2008, 72 (6), 455-82.
6. Motamedi-Shad, N.; Monsellier, E.; Torrassa, S.; Relini, A.; Chiti, F., Kinetic analysis of amyloid formation in the presence of heparan sulfate: faster unfolding and change of pathway. J. Biol. Chem., 2009, 284 (43), 29921-34.
7. Gupta-Bansal, R.; Frederickson, R.C.; Brunden, K.R., Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. J. Biol. Chem., 1995, 270 (31), 18666-71.
8. Raman, R.; Sasisekharan, V.; Sasisekharan, R., Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem. Biol., 2005, 12 (3), 267-77.
9. Yung, S.; Chan, T.M., Glycosaminoglycans and proteoglycans: overlooked entities? Perit. Dial. Int., 2007, 27 Suppl 2, S104-9.
10. Sugahara, K.; Kitagawa, H., Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. Curr. Opin. Struct. Biol., 2000, 10 (5), 518-27.
11. Sugahara, K.; Kitagawa, H., Heparin and heparan sulfate biosynthesis. IUBMB Life, 2002, 54 (4), 163-75.
12. Lin, X., Functions of heparan sulfate proteoglycans in cell signaling during development. Development, 2004, 131 (24), 6009-21.
13. Proudfoot, A.E., The biological relevance of chemokineproteoglycan interactions. Biochem. Soc. Trans., 2006, 34 (Pt 3), 422-6.
14. Ellyard, J.I.; Simson, L.; Bezos, A.; Johnston, K.; Freeman, C.; Parish, C.R., Eotaxin selectively binds heparin. An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo. J. Biol. Chem., 2007, 282 (20), 15238-47.
15. Sadir, R.; Imberty, A.; Baleux, F.; Lortat-Jacob, H., Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J. Biol. Chem., 2004, 279 (42), 43854-60.
16. Lindahl, U.; Li, J.P., Interactions between heparan sulfate and proteins-design and functional implications. Int. Rev. Cell Mol. Biol., 2009, 276, 105-59.
17. Seyrek, E.; Dubin, P., Glycosaminoglycans as polyelectrolytes. Adv. Colloid Interface Sci., 2010, 158 (1-2), 119-29.
18. Chu, C.L.; Goerges, A.L.; Nugent, M.A., Identification of common and specific growth factor binding sites in heparan sulfate proteoglycans. Biochemistry, 2005, 44 (36), 12203-13.
19. Kolset, S.O.; Prydz, K.; Pejler, G., Intracellular proteoglycans. Biochem. J., 2004, 379 (Pt 2), 217-27.
20. Kitagawa, H.; Sugahara, K., [Biosynthesis of heparan sulfate and the tumor suppressor EXT gene family]. Tanpakushitsu Kakusan Koso, 2000, 45 (4), 579-86.
21. Prydz, K.; Dalen, K.T., Synthesis and sorting of proteoglycans. J. Cell Sci., 2000, 113 Pt 2, 193-205.
22. Taylor, K.R.; Gallo, R.L., Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J., 2006, 20 (1), 9-22.
23. Wang, S.H.; Li, J.; Geng, M.Y., [Inflammatory pathology and the anti-inflammation of saccharide substances in Alzheimer's disease]. Sheng Li Ke Xue Jin Zhan, 2005, 36 (1), 67-70.
24. Taylor, K.R.; Gallo, R.L., Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation 10.1096/fj.05-4682rev. FASEB J., 2006, 20 (1), 9-22.
25. Vanpouille, C.; Deligny, A.; Delehedde, M.; Denys, A.; Melchior, A.; Lienard, X.; Lyon, M.; Mazurier, J.; Fernig, D.G.; Allain, F., The heparin/heparan sulfate sequence that interacts with cyclophilin B contains a 3-O-sulfated N-unsubstituted glucosamine residue. J. Biol. Chem., 2007, 282 (33), 24416-29.
26. Elimova, E.; Kisilevsky, R.; Ancsin, J.B., Heparan sulfate promotes the aggregation of HDL-associated serum amyloid A: evidence for a proamyloidogenic histidine molecular switch. FASEB J., 2009, 23 (10), 3436-48.
27. Properzi, F.; Carulli, D.; Asher, R.A.; Muir, E.; Camargo, L.M.; van Kuppevelt, T.H.; ten Dam, G.B.; Furukawa, Y.; Mikami, T.; Sugahara, K.; Toida, T.; Geller, H.M.; Fawcett, J.W., Chondroitin 6-sulphate synthesis is up-regulated in injured CNS, induced by injury-related cytokines and enhanced in axon-growth inhibitory glia. Eur. J. Neurosci., 2005, 21 (2), 378-90.
28. Bradbury, E.J.; Moon, L.D.; Popat, R.J.; King, V.R.; Bennett, G.S.; Patel, P.N.; Fawcett, J.W.; McMahon, S.B., Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature, 2002, 416 (6881), 636-40.
29. Yue, X.L.; Lehri, S.; Li, P.; Barbier-Chassefiere, V.; Petit, E.; Huang, Q.F.; Albanese, P.; Barritault, D.; Caruelle, J.P.; Papy-Garcia, D.; Morin, C., Insights on a new path of pre-mitochondrial apoptosis regulation by a glycosaminoglycan mimetic. Cell Death Differ., 2009, 16 (5), 770-81.
30. Zimmermann, D.R.; Dours-Zimmermann, M.T., Extracellular matrix of the central nervous system: from neglect to challenge. Histochem. Cell Biol., 2008, 130 (4), 635-53.
31. Sugahara, K.; Mikami, T.; Uyama, T.; Mizuguchi, S.; Nomura, K.; Kitagawa, H., Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate. Curr. Opin. Struct. Biol., 2003, 13 (5), 612-20.
32. Gama, C.I.; Tully, S.E.; Sotogaku, N.; Clark, P.M.; Rawat, M.; Vaidehi, N.; Goddard, W.A., 3rd; Nishi, A.; Hsieh-Wilson, L.C., Sulfation patterns of glycosaminoglycans encode molecular recognition and activity. Nat. Chem. Biol., 2006, 2 (9), 467-73.
33. Barnett, M.W.; Fisher, C.E.; Perona-Wright, G.; Davies, J.A., Signalling by glial cell line-derived neurotrophic factor (GDNF) requires heparan sulphate glycosaminoglycan. J. Cell Sci., 2002, 115 (Pt 23), 4495-503.
34. Piltonen, M.; Bespalov, M.M.; Ervasti, D.; Matilainen, T.; Sidorova, Y.A.; Rauvala, H.; Saarma, M.; Mannisto, P.T., Heparinbinding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp. Neurol., 2009, 219 (2), 499-506.
35. Ishii, M.; Maeda, N., Spatiotemporal expression of chondroitin sulfate sulfotransferases in the postnatal developing mouse cerebellum. Glycobiology, 2008, 18 (8), 602-14.
36. Galtrey, C.M.; Fawcett, J.W., The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system. Brain Res. Rev., 2007, 54 (1), 1-18.
37. Motamedi-Shad, N.; Monsellier, E.; Chiti, F., Amyloid formation by the model protein muscle acylphosphatase is accelerated by heparin and heparan sulphate through a scaffolding-based mechanism. J. Biochem., 2009, 146 (6), 805-14.
38. Naiki, H.; Nagai, Y., Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins. J. Biochem., 2009, 146 (6), 751-6.
39. Abedini, A.; Raleigh, D.P., A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides. Protein Eng. Des. Sel., 2009, 22 (8), 453-9.
40. Su, J.H.; Cummings, B.J.; Cotman, C.W., Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease. Neuroscience, 1992, 51 (4), 801-13.
41. Calamai, M.; Kumita, J.R.; Mifsud, J.; Parrini, C.; Ramazzotti, M.; Ramponi, G.; Taddei, N.; Chiti, F.; Dobson, C.M., Nature and significance of the interactions between amyloid fibrils and biological polyelectrolytes. Biochemistry, 2006, 45 (42), 12806-15.
42. Bazar, E.; Jelinek, R., Divergent Heparin-Induced Fibrillation Pathways of a Prion Amyloidogenic Determinant. Chembiochem, 2010.
43. Beyer, K., Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol., 2006, 112 (3), 237-51.
44. Han, H.; Weinreb, P.H.; Lansbury, P.T., Jr., The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem. Biol., 1995, 2 (3), 163-9.
45. Ueda, K.; Fukushima, H.; Masliah, E.; Xia, Y.; Iwai, A.; Yoshimoto, M.; Otero, D.A.; Kondo, J.; Ihara, Y.; Saitoh, T., Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1993, 90 (23), 11282-6.
46. Uversky, V.N., Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem., 2007, 103 (1), 17-37.
47. Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goedert, M., alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA, 1998, 95 (11), 6469-73.
48. Lippa, C.F.; Fujiwara, H.; Mann, D.M.; Giasson, B.; Baba, M.; Schmidt, M.L.; Nee, L.E.; O'Connell, B.; Pollen, D.A.; St George- Hyslop, P.; Ghetti, B.; Nochlin, D.; Bird, T.D.; Cairns, N.J.; Lee, V.M.; Iwatsubo, T.; Trojanowski, J.Q., Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol., 1998, 153 (5), 1365-70.
49. Spillantini, M.G.; Tolnay, M.; Love, S.; Goedert, M., Microtubuleassociated protein tau, heparan sulphate and alpha-synuclein in several neurodegenerative diseases with dementia. Acta Neuropathol., 1999, 97 (6), 585-94.
50. Lippa, C.F.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q., Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann. Neurol., 1999, 45 (3), 353-7.
51. Braak, H.; Del Tredici, K.; Rub, U.; de Vos, R.A.; Jansen Steur, E.N.; Braak, E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 2003, 24 (2), 197-211.
52. Miller, D.W.; Hague, S.M.; Clarimon, J.; Baptista, M.; Gwinn- Hardy, K.; Cookson, M.R.; Singleton, A.B., Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology, 2004, 62 (10), 1835-8.
53. Bandopadhyay, R.; de Belleroche, J., Pathogenesis of Parkinson's disease: emerging role of molecular chaperones. Trends Mol. Med., 16 (1), 27-36.
54. Chiba-Falek, O.; Lopez, G.J.; Nussbaum, R.L., Levels of alphasynuclein mRNA in sporadic Parkinson disease patients. Mov. Disord., 2006, 21 (10), 1703-8.
55. Uversky, V.N.; Li, J.; Fink, A.L., Metal-triggered structural transformations, aggregation, and fibrillation of human alphasynuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem., 2001, 276 (47), 44284-96.
56. Uversky, V.N.; Lee, H.J.; Li, J.; Fink, A.L.; Lee, S.J., Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem., 2001, 276 (47), 43495-8.
57. Shtilerman, M.D.; Ding, T.T.; Lansbury, P.T., Jr., Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry, 2002, 41 (12), 3855-60.
58. Uversky, V.N.; E, M.C.; Bower, K.S.; Li, J.; Fink, A.L., Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett, 2002, 515 (1-3), 99-103.
59. van Horssen, J.; de Vos, R.A.; Steur, E.N.; David, G.; Wesseling, P.; de Waal, R.M.; Verbeek, M.M., Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson's disease brains. J. Alzheimers Dis., 2004, 6 (5), 469-74.
60. Liu, I.H.; Uversky, V.N.; Munishkina, L.A.; Fink, A.L.; Halfter, W.; Cole, G.J., Agrin binds alpha-synuclein and modulates alphasynuclein fibrillation. Glycobiology, 2005, 15 (12), 1320-31.
61. Perry, G.; Richey, P.; Siedlak, S.L.; Galloway, P.; Kawai, M.; Cras, P., Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases. Brain Res., 1992, 579 (2), 350-2.
62. Verbeek, M.M.; Otte-Holler, I.; van den Born, J.; van den Heuvel, L.P.; David, G.; Wesseling, P.; de Waal, R.M., Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. Am. J. Pathol., 1999, 155 (6), 2115-25.
63. Minati, L.; Edginton, T.; Bruzzone, M.G.; Giaccone, G., Current concepts in Alzheimer's disease: a multidisciplinary review. Am. J. Alzheimers Dis. Other Demen, 2009, 24 (2), 95-121.
64. Berchtold, N.C.; Cotman, C.W., Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol. Aging, 1998, 19 (3), 173-89.
65. Hardy, J., The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem., 2009, 110 (4), 1129-34.
66. Valle-Delgado, J.J.; Alfonso-Prieto, M.; de Groot, N.S.; Ventura, S.; Samitier, J.; Rovira, C.; Fernandez-Busquets, X., Modulation of A{beta}42 fibrillogenesis by glycosaminoglycan structure. FASEB J., 2010.
67. Antzutkin, O.N., Amyloidosis of Alzheimer's Abeta peptides: solid-state nuclear magnetic resonance, electron paramagnetic resonance, transmission electron microscopy, scanning transmission electron microscopy and atomic force microscopy studies. Magn. Reson. Chem., 2004, 42 (2), 231-46.
68. Bitan, G.; Kirkitadze, M.D.; Lomakin, A.; Vollers, S.S.; Benedek, G.B.; Teplow, D.B., Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. USA, 2003, 100 (1), 330-5.
69. Mastrangelo, I.A.; Ahmed, M.; Sato, T.; Liu, W.; Wang, C.; Hough, P.; Smith, S.O., High-resolution atomic force microscopy of soluble Abeta42 oligomers. J. Mol. Biol., 2006, 358 (1), 106-19.
70. Fernandez-Busquets, X.; de Groot, N.S.; Fernandez, D.; Ventura, S., Recent structural and computational insights into conformational diseases. Curr. Med. Chem., 2008, 15 (13), 1336-49.
71. Arimon, M.; Diez-Perez, I.; Kogan, M.J.; Durany, N.; Giralt, E.; Sanz, F.; Fernandez-Busquets, X., Fine structure study of Abeta1-42 fibrillogenesis with atomic force microscopy. FASEB J., 2005, 19 (10), 1344-6.
72. Luhrs, T.; Ritter, C.; Adrian, M.; Riek-Loher, D.; Bohrmann, B.; Dobeli, H.; Schubert, D.; Riek, R., 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. USA, 2005, 102 (48), 17342-7.
73. Hirschfield, G.M.; Hawkins, P.N., Amyloidosis: new strategies for treatment. Int. J. Biochem. Cell Biol., 2003, 35 (12), 1608-13.
74. Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trommer, B.; Viola, K.L.; Wals, P.; Zhang, C.; Finch, C.E.; Krafft, G.A.; Klein, W.L., Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA, 1998, 95 (11), 6448-53.
75. Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 2003, 300 (5618), 486-9.
76. Tamagno, E.; Bardini, P.; Guglielmotto, M.; Danni, O.; Tabaton, M., The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic. Biol. Med., 2006, 41 (2), 202-12.
77. Walsh, D.M.; Klyubin, I.; Fadeeva, J.V.; Cullen, W.K.; Anwyl, R.; Wolfe, M.S.; Rowan, M.J.; Selkoe, D.J., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 2002, 416 (6880), 535-9.
78. Walsh, D.M.; Klyubin, I.; Fadeeva, J.V.; Rowan, M.J.; Selkoe, D.J., Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans., 2002, 30 (4), 552-7.
79. Bravo, R.; Arimon, M.; Valle-Delgado, J.J.; Garcia, R.; Durany, N.; Castel, S.; Cruz, M.; Ventura, S.; Fernandez-Busquets, X., Sulfated polysaccharides promote the assembly of amyloid beta(1-42) peptide into stable fibrils of reduced cytotoxicity. J. Biol. Chem., 2008, 283 (47), 32471-83.
80. Ancsin, J.B., Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid, 2003, 10 (2), 67-79.
81. Snow, A.D.; Kisilevsky, R.; Willmer, J.; Prusiner, S.B.; DeArmond, S.J., Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol., 1989, 77 (4), 337-42.
82. van Horssen, J.; Wesseling, P.; van den Heuvel, L.P.; de Waal, R.M.; Verbeek, M.M., Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol., 2003, 2 (8), 482-92.
83. Castillo, G.M.; Ngo, C.; Cummings, J.; Wight, T.N.; Snow, A.D., Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J. Neurochem., 1997, 69 (6), 2452-65.
84. Woods, A.G.; Cribbs, D.H.; Whittemore, E.R.; Cotman, C.W., Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate beta-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Brain Res., 1995, 697 (1-2), 53-62.
85. Madine, J.; Clayton, J.C.; Yates, E.A.; Middleton, D.A., Exploiting a (13)C-labelled heparin analogue for in situ solid-state NMR investigations of peptide-glycan interactions within amyloid fibrils. Org. Biomol. Chem., 2009, 7 (11), 2414-20.
86. Timmer, N.M.; Herbert, M.K.; Kleinovink, J.W.; Kiliaan, A.J.; de Waal, R.M.; Verbeek, M.M., Limited expression of heparan sulfate proteoglycans associated with Abeta deposits in the APPswe/PS1dE9 mouse model for Alzheimer's disease. Neuropathol. Appl. Neurobiol., 2010.
87. McLaurin, J.; Franklin, T.; Zhang, X.; Deng, J.; Fraser, P.E., Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur. J. Biochem., 1999, 266 (3), 1101-10.
88. Castillo, G.M.; Lukito, W.; Wight, T.N.; Snow, A.D., The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J. Neurochem., 1999, 72 (4), 1681-7.
89. Goedert, M.; Jakes, R.; Spillantini, M.G.; Hasegawa, M.; Smith, M.J.; Crowther, R.A. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature, 1996, 383 (6600), 550-3.
90. Valle-Delgado, J.J.; Alfonso-Prieto, M.; de Groot, N.S.; Ventura, S.; Samitier, J.; Rovira, C.; Fernandez-Busquets, X. Modulation of A{beta}42 fibrillogenesis by glycosaminoglycan structure. FASEB J.
91. Bergamaschini, L.; Rossi, E.; Storini, C.; Pizzimenti, S.; Distaso, M.; Perego, C.; De Luigi, A.; Vergani, C.; De Simoni, M.G., Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J. Neurosci., 2004, 24 (17), 4181-6.
92. Bergamaschini, L.; Rossi, E.; Vergani, C.; De Simoni, M.G., Alzheimer's disease: another target for heparin therapy. Scientific World Journal, 2009, 9, 891-908.
93. Castellani, R.J.; Lee, H.G.; Siedlak, S.L.; Nunomura, A.; Hayashi, T.; Nakamura, M.; Zhu, X.; Perry, G.; Smith, M.A., Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J. Alzheimers Dis., 2009, 18 (2), 447-52.
94. Konno, T.; Oiki, S.; Hasegawa, K.; Naiki, H., Anionic contribution for fibrous maturation of protofibrillar assemblies of the human tau repeat domain in a fluoroalcohol solution. Biochemistry, 2004, 43 (42), 13613-20.
95. Chung, S.H., Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Re.p, 2009, 42 (8), 467-74.
96. Hanger, D.P.; Anderton, B.H.; Noble, W., Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med, 2009, 15 (3), 112-9.
97. Paudel, H.K.; Li, W., Heparin-induced conformational change in microtubule-associated protein Tau as detected by chemical crosslinking and phosphopeptide mapping. J. Biol. Chem., 1999, 274 (12), 8029-38.
98. Bulic, B.; Pickhardt, M.; Schmidt, B.; Mandelkow, E.M.; Waldmann, H.; Mandelkow, E., Development of tau aggregation inhibitors for Alzheimer's disease. Angew. Chem. Int. Ed. Engl., 2009, 48 (10), 1740-52.
99. Brunden, K.R.; Trojanowski, J.Q.; Lee, V.M., Advances in taufocused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov., 2009, 8 (10), 783-93.
100. Frost, B.; Jacks, R.L.; Diamond, M.I., Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem., 2009, 284 (19), 12845-52.
101. Clavaguera, F.; Bolmont, T.; Crowther, R.A.; Abramowski, D.; Frank, S.; Probst, A.; Fraser, G.; Stalder, A.K.; Beibel, M.; Staufenbiel, M.; Jucker, M.; Goedert, M.; Tolnay, M., Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol., 2009, 11 (7), 909-13.
102. Mondragon-Rodriguez, S.; Basurto-Islas, G.; Lee, H.G.; Perry, G.; Zhu, X.; Castellani, R.J.; Smith, M.A., Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Rev. Neurother., 10 (5), 683-91.
103. Silveira, J.R.; Raymond, G.J.; Hughson, A.G.; Race, R.E.; Sim, V.L.; Hayes, S.F.; Caughey, B., The most infectious prion protein particles. Nature, 2005, 437 (7056), 257-61.
104. Cushman, M.; Johnson, B.S.; King, O.D.; Gitler, A.D.; Shorter, J., Prion-like disorders: blurring the divide between transmissibility and infectivity. J. Cell Sci., 2010, 123 (Pt 8), 1191-201.
105. Cortijo-Arellano, M.; Ponce, J.; Durany, N.; Cladera, J., Amyloidogenic properties of the prion protein fragment PrP(185-208): comparison with Alzheimer's peptide Abeta(1-28), influence of heparin and cell toxicity. Biochem. Biophys. Res. Commun., 2008, 368 (2), 238-42.
106. Fontaine, S.N.; Brown, D.R., Mechanisms of prion protein aggregation. Protein Pept. Lett., 2009, 16 (1), 14-26.
107. Volpi, N., Therapeutic applications of glycosaminoglycans. Curr. Med. Chem., 2006, 13 (15), 1799-810.
108. Klajnert, B.; Cortijo-Arellano, M.; Bryszewska, M.; Cladera, J., Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases. Biochem. Biophys. Res. Commun., 2006, 339 (2), 577-82.